Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. Sawalha Y, et al. Among authors: switchenko jm. Blood Adv. 2023 Jul 11;7(13):2983-2993. doi: 10.1182/bloodadvances.2022008916. Blood Adv. 2023. PMID: 36809796 Free PMC article.
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. Cohen JB, et al. Among authors: switchenko jm. Br J Haematol. 2015 Nov;171(4):539-46. doi: 10.1111/bjh.13637. Epub 2015 Aug 7. Br J Haematol. 2015. PMID: 26248505 Free PMC article. Clinical Trial.
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Greenwell IB, et al. Among authors: switchenko jm. Cancer. 2018 Jun 1;124(11):2306-2315. doi: 10.1002/cncr.31328. Epub 2018 Mar 26. Cancer. 2018. PMID: 29579328 Free PMC article.
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Calzada O, et al. Among authors: switchenko jm. Leuk Lymphoma. 2018 Dec;59(12):2862-2870. doi: 10.1080/10428194.2018.1455973. Epub 2018 Jun 18. Leuk Lymphoma. 2018. PMID: 29912594 Free PMC article.
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Shanmugasundaram K, et al. Eur J Haematol. 2021 Sep;107(3):301-310. doi: 10.1111/ejh.13649. Epub 2021 Jun 17. Eur J Haematol. 2021. PMID: 33973276 Free PMC article.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Karmali R, et al. Among authors: switchenko jm. Am J Hematol. 2021 Nov 1;96(11):1374-1384. doi: 10.1002/ajh.26306. Epub 2021 Aug 10. Am J Hematol. 2021. PMID: 34324220 Free PMC article.
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Bond DA, et al. Among authors: switchenko jm. Blood Adv. 2021 Dec 14;5(23):5179-5189. doi: 10.1182/bloodadvances.2021004765. Blood Adv. 2021. PMID: 34516611 Free PMC article.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Orellana-Noia VM, et al. Among authors: switchenko j. Blood. 2022 Jan 20;139(3):413-423. doi: 10.1182/blood.2021012888. Blood. 2022. PMID: 34570876 Free PMC article.
221 results